Table 1

 Patient characteristics and previous treatment

PatientsPresentation*Previous systemic treatmentDuration of disease (years)PatientPresentation*Previous systemic treatmentDuration of disease (years)
*OA, oral aphthous lesions: 6/6;
V, vasculitis in a skin biopsy: 0/6;
GU, genital ulcerations: 6/6;
C, colitis/gastrointestinal vasculitis: 1/6;
A, arthralgia/arthritis (usually a non-symmetric arthritis): 6/6;
TF, thrombophlebitis: 2/6;
SL, skin lesions: 3/6;
BU, bilateral panuveitis (severe panuveitis): 6/6.
Behçet’s disease: n = 6, mean age: 44, range 32–66
Patient 1, M; 38 years, Behçet’s diseaseOA + GU, A, TF, BUCyclosporine, colchicine, interferon alfa, prednisone6Patient 4, M; 56 years, Behçet’s diseaseOA + GU, A, SL, BUCyclosporine, colchicine, azathioprine22
Patient 2, M; 32 years, Behçet’s diseaseOA + GU, A, SL; C, BUAzathioprine, interferon alfa10Patient 5, M; 34 years, Behçet’s diseaseOA + GU, A BUInterferon alfa15
Patient 3, F; 37 years, Behçet’s diseaseOA + GU, A, TF, SL, BUCyclosporine, colchicine, interferon alfa6Patient 6, M; 66 years Behçet’s diseaseOA + GU A BUCyclosporine Interferon alfa Azathioprine, colchicine, prednisone7
Patient A, F; 31 years, idiopathic uveitisPrednisone, MTX5Patient E, F; 38 years, idiopathic uveitisPrednisone, cyclosporine4
Patient B, M; 29 years, idiopathic uveitisCyclosporine, prednisone, interferon alfa7Patient F, M; 39 years, sarcoidosisPrednisone, MTX5
Patient C, F; 62 years, idiopathic uveitisPrednisone, cyclosporine2Patient G, F; 60 years, birdshotCyclosporine, prednisone, MTX10
Patient D, M; 20 years, idiopathic uveitisCyclosporine, Cellcept, Octreotide LAR, prednisone8